Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

The Hematology Journal : the Official Journal of the European Haematology Association
J F San MiguelJ Díaz-Mediavilla

Abstract

Renal function is one of the most important prognostic factors in multiple myeloma (MM). Patients with renal failure are generally excluded from high dose therapy even though they display a poor prognosis with conventional chemotherapy schemes. The aim of this study was to analyze the outcome of MM patients with renal insufficiency undergoing autologous stem cell transplantation (ASCT), including the evaluation of the quality of PB stem cell collections, kinetics of engraftment, transplant-related mortality, response to high dose chemotherapy and survival. From a total of 566 valuable patients included in the MM Spanish ASCT registry, three groups of patients were defined: group BA, patients with abnormal renal function at diagnosis but normal at transplant (73 cases); group BB, patients with abnormal function both at diagnosis and at transplant (14 cases); and group AA (control group, 479 cases), patients who constantly had normal renal function. Patients from groups BA and BB presented with a significantly higher number of adverse prognostic factors, reflecting that we were dealing with high tumor MM cases, as compared with patients from group AA. The number of mononuclear cells, CD34+ cells and CFU-GM cells collected in pati...Continue Reading

Citations

Jul 7, 2011·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·Ajay Gupta, Lalit Kumar
Oct 18, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M J EllisU D Patel
Feb 22, 2012·Nature Reviews. Nephrology·Colin A HutchisonUNKNOWN International Kidney and Monoclonal Gammopathy Research Group
Oct 11, 2013·Blood·Jean-Paul FermandUNKNOWN International Kidney and Monoclonal Gammopathy Research Group
Aug 9, 2006·Seminars in Dialysis·Jeffrey G Penfield
Oct 6, 2005·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Tarek M El-AchkarJesus Dominguez
Sep 9, 2017·Current Opinion in Nephrology and Hypertension·Colin A HutchisonPeter Mollee
Apr 30, 2003·Current Treatment Options in Oncology·Jesús F San Miguel, Ramón García-Sanz
Jul 14, 2007·Expert Review of Anticancer Therapy·Patrizia FalcoAntonio Palumbo
Aug 26, 2006·Nature Clinical Practice. Nephrology·François Madore
Jan 7, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Marion Haubitz, Dietrich Peest
Jun 6, 2008·Leukemia·M A DimopoulosH Ludwig
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Jean-Luc Harousseau
Sep 4, 2007·The Oncologist·Rami ManochakianAsher A Chanan-Khan
May 1, 2007·Current Hematologic Malignancy Reports·Shaji Kumar
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Oct 21, 2016·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios A Dimopoulos
Jul 19, 2016·Expert Review of Hematology·Despoina FotiouEfstathios Kastritis
Mar 16, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosEvangelos Terpos
Nov 30, 2019·Stem Cells International·Hongfei ZhongGaosi Xu
Apr 30, 2003·Current Treatment Options in Oncology·Sandeep R Pandit, David H Vesole
Jan 18, 2006·British Journal of Haematology·Alastair SmithUNKNOWN British Committee for Standards in Haematology
Jun 11, 2005·European Journal of Haematology·Lene M KnudsenChristian Geisler
May 17, 2011·British Journal of Haematology·Jennifer M BirdUNKNOWN Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum
Nov 26, 2010·The Annals of Pharmacotherapy·Kelly M GregoryPaul M Armistead
Aug 24, 2007·Expert Opinion on Investigational Drugs·Pellegrino Musto, Fiorella D'Auria
May 28, 2013·Expert Opinion on Pharmacotherapy·Efstathios KastritisMeletios A Dimopoulos
Aug 4, 2006·Journal of the American Society of Nephrology : JASN·Stephen M Korbet, Melvin M Schwartz
Nov 28, 2001·Hematology·W S DaltonJ L Harousseau
Feb 14, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Asher A Chanan-KhanMeletios A Dimopoulos
Mar 23, 2021·British Journal of Haematology·Jonathan SiveUNKNOWN British Society of Haematology
Jul 20, 2005·Best Practice & Research. Clinical Haematology·Joan Bladé, Laura Rosiñol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.